Abstract: This application describes examples of a circuit board, a controller, and a vehicle. In one example, the controller of the vehicle includes a first circuit board, a second circuit board, a radio frequency module, and a control chip. A first connector is disposed on the first circuit board, and a second connector is disposed on the second circuit board. The first circuit board is detachably mounted to the second circuit board through a connection between a first connector and a second connector.

Abstract: Disclosed herein are the use of thiazolidinediones for the treatment of digestive diseases including gastroparesis.

Abstract: Disclosed herein are thiazolidinediones for the treatment of kidney diseases, glomerular diseases, and nephrotic syndrome.

Abstract: This application relates to an intelligent connected vehicle technology, and provides a circuit board, a controller, and a vehicle, to reduce manufacturing costs of the vehicle and facilitate vehicle structure miniaturization. A control module of the controller of the vehicle includes a first circuit board, a radio frequency module, and a control chip. The radio frequency module is mounted on the first circuit board and is configured to electrically connect to an antenna that receives and transmits a signal with a base station; and the control chip is mounted on the first circuit board and is configured to control the radio frequency module.

Abstract: The present invention relates to pharmaceutical compositions for administration to mammals that include (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient that provides pharmacokinetic profiles useful for the treatment of neurodegenerative diseases.

Abstract: This invention relates to pharmaceutical compositions for enhancing the solubility of (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol and salt forms thereof.

Abstract: The invention is directed to a novel crystalline S-apomorphine hydrochloride hydrate salt.

Abstract: The invention is directed to 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol for the treatment of diseases mediated by protein misfolding, heat shock factor 1 pathways, or nuclear erythroid 2-related factor 2 pathways.

Abstract: The present disclosure relates to methods, systems, and non-transitory computer readable media for receiving, at an authentication service of an enterprise network and from a user device, a request to access an application; determining a user status associated with the request based on information received from at least an identity service engine; determining, based on the user status, whether the user device meets a set of security parameters for accessing the application, to yield a determination; and determining, based on the determination, whether to grant or deny the request for accessing the application.

Abstract: The invention is directed to (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H- dibenzo[de,g]quinoline-10,11-diol for the treatment of diseases mediated by protein misfolding of Cu/Zn Superoxide Dismutase (SOD1) or mediated by astrocyte toxicity affecting motor neuron survival.

Abstract: The invention is directed to a novel crystalline S-apomorphine hydrochloride hydrate salt.

Abstract: Sublingual formulations containing an opioid, preferably, fentanyl or a pharmaceutically acceptable salt or ester thereof, naloxone or a pharmaceutically acceptable salt or ester thereof, and a terpene; as well as methods of treating pain by administering the formulations of the invention to a patient in need thereof.

Abstract: The invention relates to the preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid. The invention also relates to the use of the novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid in pharmaceutical compositions in drug delivery systems for humans. The invention further relates to the use of the novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid or the pharmaceutical compositions thereof to treat and/or prevent a disease state associated with osteoporosis, tumor induced hypercalcemia (TIH), cancer-induced bone metastasis, Paget's disease or for adjuvant or neoadjuvant therapies.

Abstract: Preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.

Abstract: Sublingual formulations containing an opioid, preferably, fentanyl or a pharmaceutically acceptable salt or ester thereof, naloxone or a pharmaceutically acceptable salt or ester thereof, and a terpene; as well as methods of treating pain by administering the formulations of the invention to a patient in need thereof.

Abstract: Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.

Abstract: Preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.

Abstract: Sublingual formulations containing an opioid, preferably, fentanyl or a pharmaceutically acceptable salt or ester thereof, naloxone or a pharmaceutically acceptable salt or ester thereof, and a terpene; as well as methods of treating pain by administering the formulations of the invention to a patient in need thereof.

Abstract: Preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.

Abstract: Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.